World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
66
Citations
17029
World Ranking
8595
National Ranking
81

Overview

Leif R. Lund is affiliated with the University of Copenhagen in Denmark. Their research contributions are focused primarily within the field of medicine, with a particular emphasis on infectious diseases, surgery, and pulmonary and respiratory medicine.

The following recent paper highlights their work: Pyeloduodenal fistula: a review of the current literature, published in 2024 in International Urology and Nephrology.

The main topics addressed in their research include:

  • Infectious Disease Case Reports and Treatments
  • Abdominal vascular conditions and treatments
  • Biliary and Gastrointestinal Fistulas

Frequent coauthors collaborating with Leif R. Lund comprise:

  • K Spanggaard
  • N K Hvid
  • M Diatchikhine
  • T H Olesen

Leif R. Lund has published notably in the following venue:

  • International Urology and Nephrology

Their research outputs encompass case reviews and clinical investigations that contribute to the understanding of complex disease processes and treatment approaches within their subfields. Their work on pyeloduodenal fistulas represents an example of analyzing rare clinical entities through literature review formats to inform medical practice.

Best Publications

  • Impaired wound healing in mice with a disrupted plasminogen gene.

    J Romer;T H Bugge;T H Bugge;C Pyke;L R Lund

  • Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis.

    Ann L. Roldan;Maria Vittoria Cubellis;Maria Teresa Masucci;Niels Behrendt

  • Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and -dependent pathways.

    Leif R. Lund;John Rømer;Nicole Thomasset;Helene Solberg

  • Matrix Metalloproteinase 9 and Vascular Endothelial Growth Factor Are Essential for Osteoclast Recruitment into Developing Long Bones

    Michael T. Engsig;Qing-Jun Chen;Thiennu H. Vu;Anne-Cecilie Pedersen

  • Plasminogen activator inhibitors: hormonally regulated serpins

    Peter A. Andreasen;Birgitte Georg;Leif R. Lund;Andrea Riccio

  • Plasminogen activation and cancer

    Keld Danø;Niels Behrendt;Gunilla Høyer-Hansen;Morten Johnsen

  • Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation

    Morten Johnsen;Leif R Lund;John Rømer;Kasper Almholt

  • The Plasminogen Activator Inhibitor PAI-1 Controls In Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin: Implications for Antiangiogenic Strategies

    Khalid Bajou;Véronique Masson;Robert D. Gerard;Petra M. Schmitt

  • The gamma 2 chain of kalinin/laminin 5 is preferentially expressed in invading malignant cells in human cancers.

    C. Pyke;J. Rømer;P. Kallunki;L. R. Lund

  • Cancer invasion and tissue remodeling--cooperation of protease systems and cell types.

    Keld Danø;John Rømer;Boye S. Nielsen;Signe Bjørn

  • Site-specific inductive and inhibitory activities of MMP-2 and MMP-3 orchestrate mammary gland branching morphogenesis

    Bryony S. Wiseman;Mark D. Sternlicht;Leif R. Lund;Caroline M. Alexander

  • Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo.

    Andreas E. May;Sandip M. Kanse;Leif R. Lund;Roland H. Gisler

  • Functional overlap between two classes of matrix‐degrading proteases in wound healing

    Leif R. Lund;John Rømer;Thomas H. Bugge;Boye S. Nielsen

  • Interleukin (IL)-23 mediates Toxoplasma gondii-induced immunopathology in the gut via matrixmetalloproteinase-2 and IL-22 but independent of IL-17.

    Melba Muñoz;Markus M. Heimesaat;Kerstin Danker;Daniela Struck

  • One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity.

    L C Petersen;L R Lund;L S Nielsen;K Danø

  • Impaired wound contraction in stromelysin-1-deficient mice.

    Kelli M. Bullard;Leif Lund;John S. Mudgett;Theodore N. Mellin

  • Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain.

    G Høyer-Hansen;E Rønne;H Solberg;N Behrendt

  • Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts.

    L. R. Lund;A. Riccio;P. A. Andreasen;L. S. Nielsen

  • Proteinases in bone resorption: obvious and less obvious roles

    Jean-Marie Delaissé;Michael T Engsig;Vincent Everts;Maria del Carmen Ovejero

  • Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans.

    J. Grøndahl-Hansen;E. Ralfkiaer;L. T. Kirkeby;P. Kristensen

Frequent Co-Authors

Keld Danø
Keld Danø Copenhagen University Hospital
Peter A. Andreasen
Peter A. Andreasen Aarhus University
Boye Schnack Nielsen
Boye Schnack Nielsen Bioneer (Denmark)
Zena Werb
Zena Werb University of California, San Francisco
Andrea Riccio
Andrea Riccio University of Campania "Luigi Vanvitelli"
Niels Behrendt
Niels Behrendt Technical University of Denmark
Michael Ploug
Michael Ploug University of Copenhagen
Gunilla Høyer-Hansen
Gunilla Høyer-Hansen University of Copenhagen
Jay L. Degen
Jay L. Degen Cincinnati Children's Hospital Medical Center
Thomas H. Bugge
Thomas H. Bugge National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Leif R. Lund

Recently Published Articles